Investigation Overview
June 13, 2014 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares, was announced concerning whether the takeover of Idenix Pharmaceuticals Inc . by Merck for $24.50 per shares is unfair to NASDAQ:IDIX stockholders. The investigation by a law firm concerns whether certain officers and direct...
You must register (for free) or login to view the entire investigation.